| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $2,678,891 | 16 | 100 |
| Froimson Mark | director | 0 | $0 | 1 | $10,905 | $-10,905 |
| SLONIN JONATHAN | Chief Medical Officer | 0 | $0 | 3 | $240,432 | $-240,432 |
| RIKER LAUREN | Senior Vice President, Finance | 0 | $0 | 4 | $479,186 | $-479,186 |
| WILLIAMS KRISTEN | Chief Administrative Officer | 0 | $0 | 2 | $498,171 | $-498,171 |
| Cross Shawn | Chief Financial Officer | 0 | $0 | 6 | $1.45M | $-1.45M |
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira …
Over the last 12 months, insiders at Pacira BioSciences, Inc. have bought $0 and sold $2.68M worth of Pacira BioSciences, Inc. stock.
On average, over the past 5 years, insiders at Pacira BioSciences, Inc. have bought $215,684 and sold $4.11M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,512 shares for transaction amount of $20,034 was made by BIGAL MARCELO (director) on 2024‑08‑16.
| 2026-10-08 | Sale | RIKER LAUREN | Senior Vice President, Finance | 6,000 0.0152% | $36.32 | $217,920 | -0.03% | |
| 2026-08-17 | Sale | SLONIN JONATHAN | Chief Medical Officer | 3,040 0.0077% | $23.23 | $70,619 | +11.14% | |
| 2026-06-11 | Sale | RIKER LAUREN | Senior Vice President, Finance | 6,115 0.0156% | $23.50 | $143,703 | +9.20% | |
| 2026-06-04 | Sale | WILLIAMS KRISTEN | Chief Administrative Officer | 10,259 0.0256% | $22.27 | $228,468 | +12.00% | |
| 2026-04-23 | Sale | Cross Shawn | Chief Financial Officer | 12,941 0.0298% | $25.16 | $325,596 | -1.01% | |
| 2026-04-22 | Sale | Cross Shawn | Chief Financial Officer | 1,500 0.0035% | $25.01 | $37,515 | +0.96% | |
| 2026-04-20 | Sale | Cross Shawn | Chief Financial Officer | 7,714 0.0181% | $25.14 | $193,930 | +0.76% | |
| 2026-03-17 | Sale | SLONIN JONATHAN | Chief Medical Officer | 3,261 0.0079% | $22.82 | $74,416 | +13.15% | |
| 2026-03-17 | Sale | Froimson Mark | director | 500 0.0012% | $21.81 | $10,905 | +13.15% | |
| 2026-02-02 | Sale | WILLIAMS KRISTEN | Chief Administrative Officer | 13,137 0.0295% | $20.53 | $269,703 | +14.87% | |
| 2026-02-02 | Sale | RIKER LAUREN | Senior Vice President, Finance | 4,000 0.0091% | $20.81 | $83,240 | +14.87% | |
| 2026-01-05 | Sale | RIKER LAUREN | Senior Vice President, Finance | 1,416 0.003% | $24.24 | $34,324 | -4.22% | |
| 2025-12-10 | Sale | Cross Shawn | Chief Financial Officer | 9,104 0.0203% | $25.14 | $228,875 | -2.98% | |
| 2025-12-09 | Sale | Cross Shawn | Chief Financial Officer | 15,896 0.0353% | $25.03 | $397,877 | -1.35% | |
| 2025-11-17 | Sale | SLONIN JONATHAN | Chief Medical Officer | 3,960 0.0088% | $24.09 | $95,396 | +2.01% | |
| 2025-11-10 | Sale | Cross Shawn | Chief Financial Officer | 12,060 0.0266% | $22.09 | $266,405 | +4.70% | |
| 2025-09-04 | Sale | Ceesay Abraham | director | 2,354 0.0053% | $27.19 | $64,005 | -11.39% | |
| 2025-08-07 | Sale | BIGAL MARCELO | director | 4,912 0.0109% | $23.67 | $116,267 | -0.08% | |
| 2025-06-04 | Sale | WILLIAMS KRISTEN | Chief Administrative Officer | 14,376 0.0302% | $26.24 | $377,226 | -13.05% | |
| 2025-06-04 | Sale | RIKER LAUREN | Senior Vice President, Finance | 5,578.34 0.0117% | $26.21 | $146,208 | -13.05% |
| Froimson Mark | director | 20136 0.0505% | $732,749.04 | 2 | 3 | +41.3% |
| GORDON CARL L | director | 2828941 7.0969% | $102.95M | 1 | 0 | +33.11% |
| KAILIAN VAUGHN M | 2790479 7.0004% | $101.55M | 3 | 1 | +45.51% | |
| MPM BioVentures IV QP LP | 2790479 7.0004% | $101.55M | 3 | 1 | +45.51% | |
| ORBIMED ADVISORS LLC | 10 percent owner | 2446000 6.1362% | $89.01M | 1 | 9 | +33.11% |
| HBM Healthcare Investments (Cayman) Ltd. | 10 percent owner | 2233993 5.6043% | $81.3M | 2 | 6 | +43.57% |
| Wicki Andreas | director | 451324 1.1322% | $16.42M | 2 | 72 | +43.57% |
| Sanderling Venture Partners VI LP | director | 416083 1.0438% | $15.14M | 1 | 5 | +33.11% |
| STACK DAVID M | CEO and Chairman | 153781 0.3858% | $5.6M | 1 | 45 | +35.49% |
| Lee Frank D. | Chief Executive Officer | 107784 0.2704% | $3.92M | 1 | 0 | +83.69% |
| WINSTON ROY | Chief Medical Officer | 52440 0.1316% | $1.91M | 1 | 9 | +64.83% |
| Scibetta James S | President | 25118 0.063% | $914,044.02 | 2 | 13 | +5.63% |
| PACE GARY W | director | 22127 0.0555% | $805,201.53 | 5 | 6 | +11.64% |
| LONGENECKER JOHN P PHD | 18823 0.0472% | $684,968.97 | 1 | 12 | <0.0001% | |
| Kronenfeld Mark A. | director | 17897 0.0449% | $651,271.83 | 5 | 2 | +14.69% |
| Brege Laura | director | 17552 0.044% | $638,717.28 | 1 | 6 | +76.51% |
| Jones James B | SVP & Chief Medical Officer | 16823 0.0422% | $612,188.97 | 2 | 2 | <0.0001% |
| HASTINGS PAUL J | director | 12724 0.0319% | $463,026.36 | 1 | 18 | +79.52% |
| BIGAL MARCELO | director | 11393 0.0286% | $414,591.27 | 2 | 1 | +80.1% |
| Braunstein Scott | SVP, Strategy & Corp. Dev. | 9982 0.025% | $363,244.98 | 1 | 1 | <0.0001% |
| YANG MICHAEL J. | director | 7230 0.0181% | $263,099.70 | 1 | 0 | +82.12% |
| WINGER DENNIS L | director | 2645 0.0066% | $96,251.55 | 1 | 0 | <0.0001% |
| Markvicka Taunia | SVP, Chief Commercial Officer | 230 0.0006% | $8,369.70 | 1 | 4 | <0.0001% |
| EVNIN LUKE | director | 0 0% | $0 | 3 | 15 | +45.51% |
| MIDDLETON FRED A | director | 0 0% | $0 | 2 | 5 | +43.57% |
$1,279,728,023 | 131 | 10.76% | $3.05B | |
$25,613,591 | 65 | -3.30% | $12.27B | |
$14,599,168 | 59 | 12.79% | $1.66B | |
Pacira BioSciences, Inc. (PCRX) | $102,709,455 | 46 | 30.55% | $1.45B |
$73,762,556 | 45 | -9.99% | $2.17B |
| Increased Positions | 135 | +50.37% | 5M | +9.93% |
| Decreased Positions | 118 | -44.03% | 6M | -11.63% |
| New Positions | 50 | New | 1M | New |
| Sold Out Positions | 25 | Sold Out | 991,366 | Sold Out |
| Total Postitions | 285 | +6.34% | 47M | -1.7% |
| Blackrock, Inc. | $179,443.00 | 17.06% | 7.34M | -459,831 | -5.9% | 2025-09-30 |
| Vanguard Group Inc | $127,132.00 | 12.09% | 5.2M | -208,397 | -3.85% | 2025-09-30 |
| Doma Perpetual Capital Management Llc | $66,074.00 | 6.28% | 2.7M | +897,255 | +49.73% | 2025-09-30 |
| Dimensional Fund Advisors Lp | $52,919.00 | 5.03% | 2.16M | +11,831 | +0.55% | 2025-09-30 |
| Renaissance Technologies Llc | $52,300.00 | 4.97% | 2.14M | -257,400 | -10.74% | 2025-09-30 |
| D. E. Shaw & Co., Inc. | $47,505.00 | 4.52% | 1.94M | -311,222 | -13.81% | 2025-09-30 |
| State Street Corp | $46,488.00 | 4.42% | 1.9M | -50,047 | -2.57% | 2025-09-30 |
| Balyasny Asset Management L.P. | $46,109.00 | 4.38% | 1.89M | -245,662 | -11.53% | 2025-09-30 |
| American Century Companies Inc | $33,718.00 | 3.21% | 1.38M | +196,000 | +16.57% | 2025-09-30 |
| Goldman Sachs Group Inc | $32,042.00 | 3.05% | 1.31M | +1,087 | +0.08% | 2025-09-30 |